Equities Analysts Offer Predictions for Xencor Q3 Earnings

Key Points

• Wedbush analysts have raised Xencor's Q3 2025 earnings estimate to ($0.51) per share from ($0.79), maintaining an "Outperform" rating with a target price of $26.00.
• Xencor reported quarterly earnings of ($0.41) EPS, outperforming the consensus estimate of ($0.78), with a year-over-year revenue increase of 82.4% to $43.61 million.
• Despite the positive earnings forecast, Barclays downgraded its target price for Xencor from $22.00 to $6.00 and set an "underweight" rating, reflecting varied analyst opinions on the stock.

Xencor, Inc. (NASDAQ:XNCR - Free Report) - Investment analysts at Wedbush upped their Q3 2025 EPS estimates for Xencor in a research report issued to clients and investors on Thursday, August 7th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will earn ($0.51) per share for the quarter, up from their previous estimate of ($0.79). Wedbush has a "Outperform" rating and a $26.00 price objective on the stock. The consensus estimate for Xencor's current full-year earnings is ($3.68) per share. Wedbush also issued estimates for Xencor's Q4 2025 earnings at ($0.84) EPS, FY2025 earnings at ($2.43) EPS, Q1 2026 earnings at ($0.86) EPS, Q2 2026 earnings at ($0.86) EPS, Q3 2026 earnings at ($0.86) EPS, Q4 2026 earnings at ($0.87) EPS, FY2026 earnings at ($3.45) EPS, FY2027 earnings at ($3.38) EPS and FY2028 earnings at ($3.75) EPS.

A number of other brokerages have also issued reports on XNCR. Wells Fargo & Company dropped their price objective on shares of Xencor from $33.00 to $27.00 and set an "overweight" rating for the company in a report on Thursday, August 7th. Barclays reduced their price objective on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a research report on Thursday, May 8th. Finally, William Blair assumed coverage on shares of Xencor in a research report on Monday, April 21st. They set an "outperform" rating for the company. Two equities research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $26.43.

Xencor Stock Down 3.7%

Shares of XNCR stock traded down $0.29 on Monday, reaching $7.44. The company had a trading volume of 194,560 shares, compared to its average volume of 767,628. The stock has a market capitalization of $530.26 million, a PE ratio of -3.13 and a beta of 0.89. Xencor has a one year low of $6.92 and a one year high of $27.24. The business's 50-day moving average is $8.58 and its 200 day moving average is $10.74.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.78) by $0.37. The firm had revenue of $43.61 million for the quarter, compared to the consensus estimate of $22.59 million. Xencor had a negative net margin of 121.52% and a negative return on equity of 25.75%. The business's revenue for the quarter was up 82.4% on a year-over-year basis. During the same period in the prior year, the company posted ($1.07) earnings per share.

Insider Buying and Selling at Xencor

In other news, Director Kurt A. Gustafson sold 2,993 shares of the firm's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $9.22, for a total transaction of $27,595.46. Following the completion of the transaction, the director directly owned 20,183 shares in the company, valued at $186,087.26. This trade represents a 12.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ellen Feigal sold 2,993 shares of Xencor stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $9.22, for a total value of $27,595.46. Following the completion of the sale, the director owned 19,183 shares of the company's stock, valued at $176,867.26. The trade was a 13.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 11,194 shares of company stock valued at $103,209. 4.76% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Xencor

A number of large investors have recently made changes to their positions in the company. HighVista Strategies LLC lifted its position in shares of Xencor by 4.3% during the 2nd quarter. HighVista Strategies LLC now owns 33,304 shares of the biopharmaceutical company's stock valued at $262,000 after buying an additional 1,362 shares in the last quarter. iSAM Funds UK Ltd purchased a new position in Xencor in the 2nd quarter worth approximately $122,000. WINTON GROUP Ltd lifted its holdings in Xencor by 6.1% in the 2nd quarter. WINTON GROUP Ltd now owns 91,241 shares of the biopharmaceutical company's stock worth $717,000 after purchasing an additional 5,271 shares in the last quarter. Cerity Partners LLC purchased a new position in Xencor in the 2nd quarter worth approximately $195,000. Finally, Jump Financial LLC raised its holdings in shares of Xencor by 151.6% during the 2nd quarter. Jump Financial LLC now owns 126,972 shares of the biopharmaceutical company's stock worth $998,000 after acquiring an additional 76,499 shares in the last quarter.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.